Core Viewpoint - Liaoning Chengda's stock price has experienced a decline of 2.03% on December 2, with a current price of 11.56 CNY per share and a total market capitalization of 17.683 billion CNY. The company has seen a year-to-date stock price increase of 11.91%, but has faced declines over various time frames, including a 3.67% drop in the last five trading days and an 8.40% drop in the last 20 days [1]. Financial Performance - For the period from January to September 2025, Liaoning Chengda reported operating revenue of 8.114 billion CNY, a year-on-year decrease of 2.03%. However, the net profit attributable to shareholders increased significantly by 91.83% to 1.365 billion CNY [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Liaoning Chengda decreased by 8.64% to 60,300, while the average circulating shares per person increased by 9.45% to 25,364 shares [2]. - The company has distributed a total of 2.11 billion CNY in dividends since its A-share listing, with 411 million CNY distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, the Southern CSI 500 ETF ranked as the sixth largest shareholder with 13.3903 million shares, a decrease of 320,200 shares from the previous period. The Hong Kong Central Clearing Limited was the eighth largest shareholder with 10.3398 million shares, down by 1.5325 million shares [3].

截至2025年11月25日收盘，辽宁成大（600739）报收于12.0元，较前一交易日上涨0.84%，最新总市值 为183.57亿元。该股当日开盘11.9元，最高12.1元，最低11.9元，成交额达1.39亿元，换手率为0.76%。 同日，辽宁成大发布公告称，公司将于2025年12月10日召开第四次临时股东会，审议《关于公司全资子 公司向关联参股公司提供担保的议案》。根据公告内容，公司全资子公司成大医疗拟为其参股公司成大 医院向大连银行申请的40,000万元贷款及授信提供担保。其中，成大医疗按持股比例为6,000万元提供连 带责任保证担保，并以其持有的成大医院15%股权提供质押担保。成大医院其他股东及实际控制人也将 按各自持股比例提供相应担保。由于成大医疗持有成大医院15%股权，且公司副总裁兼任成大医院董 事，本次交易构成关联交易。本次担保事项将提交股东大会审议，关联股东需回避表决，且议案对中小 投资者进行单独计票。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《辽宁成大股份有限公司2025年第四次临时股东会会议文 ...

0 辽宁成大股份有限公司 2025 年第四次临时股东会会议文件目录 | 2025 | 年第四次临时股东会会议议程 2 | | --- | --- | | 关于公司全资子公司向关联参股公司提供担保的议案 4 | | 1 辽宁成大股份有限公司 会议表决方式：采用现场投票与网络投票相结合的方式 现场会议地点：公司会议室 现场会议主持人：董事长 徐飚先生 2025 年第四次临时股东会会议议程 会议时间： 一、现场会议时间：2025 年 12 月 10 日 14 点 00 分 二、网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自 2025 年 12 月 10 日 至 2025 年 12 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 会议出席对象： 一、股权登记日收市后在中国证券登记结算有限责任公司上海分公司登记在 册的公司股东有权出席股东会（具体情况详见下表）， ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025-081 辽宁成大股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第四次临时股东会 召开的日期时间：2025 年 12 月 10 日 14 点 00 分 召开地点：公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年12月10日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 10 日 至2025 年 12 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-1 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Liaoning Chengda Medical Service Management Co., Ltd., will provide a guarantee for a loan application by its associated company, Chengda Hospital, to improve cash flow and reduce financial costs [2][3]. Group 1: Guarantee Details - Chengda Hospital plans to apply for a fixed asset loan of 370 million yuan from Dalian Bank to replace existing loans and a comprehensive credit line of 30 million yuan, totaling 400 million yuan [2]. - Chengda Medical will provide a guarantee of 60 million yuan based on its 15% equity stake in Chengda Hospital, using joint liability guarantee and equity pledge as the guarantee methods [2][3]. - Other shareholders will also provide guarantees according to their respective equity stakes, and Chengda Hospital will use its land use rights and buildings as collateral for the loan [2][3]. Group 2: Internal Decision-Making Process - The guarantee matter has been approved by the company's board of directors and independent directors in their respective meetings [4][9]. - The proposal will be submitted for approval at the company's shareholders' meeting [5]. Group 3: Credit Status and Necessity of Guarantee - Chengda Hospital has a good credit status and is not classified as a dishonest executor [7]. - The guarantee is deemed necessary and reasonable to support Chengda Hospital's business development needs, with no harm to the interests of the company or its shareholders [7][8]. Group 4: Board and Independent Directors' Opinions - Independent directors agree that the guarantee will not affect the company's independence and will not harm the interests of shareholders, especially minority shareholders [8]. - The board of directors has unanimously approved the proposal to provide the guarantee [9].

Core Viewpoint - The company has decided to permanently suspend its subsidiary, Xinjiang Baoming Mining Co., Ltd., due to ongoing operational challenges and financial losses, while also planning to provide guarantees for a related party's loan to improve cash flow [8][14][18]. Group 1: Board Meeting Decisions - The company's board held a meeting on November 21, 2025, where all nine directors attended and unanimously approved the proposal for the long-term suspension of Xinjiang Baoming Mining [1][3]. - The board also approved a proposal for the company’s wholly-owned subsidiary to provide guarantees for a related party's loan, which will require further approval from the shareholders' meeting [2][20]. Group 2: Xinjiang Baoming Mining's Situation - Xinjiang Baoming Mining has been temporarily suspended since January 31, 2024, due to the lack of necessary land permits, which has severely impacted its production capacity [9][11]. - The company has incurred significant losses, with Xinjiang Baoming reporting a revenue of 0.19 billion yuan in 2024, contributing only 0.17% to the company's total revenue, and a loss of 0.926 billion yuan [14]. - As of the announcement date, Xinjiang Baoming remains in a suspended state, with ongoing efforts to secure land and production permits, but the timeline for resuming operations is uncertain [13][14]. Group 3: Financial Implications - The long-term suspension of Xinjiang Baoming is expected to necessitate adjustments in asset valuation, potentially impacting the company's short-term financial status negatively, while aligning with long-term strategic goals [14][15]. - In 2024, the company achieved a revenue of 11.289 billion yuan and a net profit of 2.1 billion yuan, while Xinjiang Baoming's contribution was minimal, indicating a significant financial burden from the subsidiary's losses [14]. Group 4: Future Strategy - The company aims to focus on core industries such as biomedicine and explore new investment opportunities in line with national industrial policies, while seeking strategic investors for Xinjiang Baoming to address its financial challenges [15].

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Viewpoint - Liaoning Chengda Co., Ltd. has decided to implement a long-term suspension of its subsidiary Xinjiang Baoming Mining Co., Ltd. as a strategic move for resource optimization and transformation [1] Group 1: Company Actions - The board of directors approved the long-term suspension of Xinjiang Baoming Mining, indicating a significant step in the company's resource allocation strategy [1] - The mining area of Baoming covers approximately 70 square kilometers, with a resource reserve of 1.27 billion tons and shale oil equivalent exceeding 70 million tons [1] - Due to complex factors such as land approval and production licensing, Baoming Mining has been in a state of suspension since 2024, facing considerable operational challenges [1] Group 2: Financial Performance - In 2024, the company achieved an operating income of 11.289 billion yuan and a net profit attributable to shareholders of 210 million yuan; Baoming Mining contributed 1.9 million yuan, accounting for 0.17% of total revenue [2] - In the first three quarters of 2025, the company reported an operating income of 8.114 billion yuan and a net profit of 1.365 billion yuan; Baoming Mining's revenue was 300,000 yuan, representing 0.03% of total revenue [2] Group 3: Strategic Focus - The long-term suspension is expected to help the company concentrate on its core business and enhance the execution of its new productivity strategy [2] - The company plans to leverage its solid financial asset base to focus on high-tech industries such as biomedicine, aligning with national policy directions to explore investment opportunities in new productivity-related sectors for high-quality development [2]

Core Viewpoint - The company, Liaoning Chengda, has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not provide further large cash injections, focusing instead on attracting strategic investors and shifting its focus towards core industries like biomedicine [1] Group 1: Company Strategy and Management - The new management team, elected in February, is actively optimizing the financing structure and controlling funding costs to ensure stable operations across all business segments [2] - The company has issued short-term financing bonds with decreasing interest rates, indicating a successful reduction in financing costs [2] - The management aims to enhance the company's core competitiveness and sustainable development through non-public issuance of exchangeable bonds [3] Group 2: Financial Performance and Investments - The company has seen significant growth in investment income from its holdings in Guangfa Securities and China Insurance, with year-on-year increases of 53.19% and 143.94%, respectively [4] - The capital market has rebounded, contributing to the increase in asset values and overall financial performance [4] Group 3: Focus on Biomedicine - The company has partnered with the Chinese Academy of Sciences to establish an AI-based vaccine research laboratory, aiming to enhance innovation in vaccine development [6] - Ongoing collaborations with the Chinese Academy of Microbiology focus on infectious disease prevention, with several vaccine candidates in various stages of clinical trials [7] - The company is expanding its vision beyond human vaccines to explore early-stage biopharmaceutical technologies and potential mergers and acquisitions to create a second growth curve [7]

Core Viewpoint - Liaoning Chengda Co., Ltd. has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not make further large cash investments, focusing instead on introducing strategic investors to address funding and development issues [1] Group 1: Management Changes - The company held its first temporary shareholders' meeting in 2025, where the board of directors was re-elected, and Xu Biao was elected as the chairman [1] - Xu Biao has extensive experience and familiarity with the company, having served on the board since 2020 and currently holding positions in Guangdong Minying Investment Co., Ltd. [1] - Zhang Shanwei, the new president, has a background in industrial investment and management, contributing to the company's strategic direction [2] Group 2: Strategic Focus and Collaborations - The new management team is promoting a culture of achievement and openness, aiming for a shift towards innovative development and technology [2] - Liaoning Chengda's subsidiary, Chengda Bio, has signed a cooperation agreement with Zhongke Zhidong Taichu to establish an "AI + Vaccine Research Joint Laboratory" [2] - A strategic cooperation agreement was also signed with the Institute of Microbiology of the Chinese Academy of Sciences, focusing on emerging infectious diseases [2][3] Group 3: Financial Strategies and Debt Management - The company is optimizing its debt structure and enhancing its financing capabilities, which has led to a reduction in financing costs [3] - In 2025, the company issued short-term financing bonds totaling 14 billion yuan, with decreasing interest rates [3] - The company plans to issue exchangeable bonds to improve resource allocation and strengthen its core competitiveness [4]